Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates

Chad Mire, Andrew D. Miller, Angela Carville, Susan V. Westmoreland, Joan B. Geisbert, Keith G. Mansfield, Heinz Feldmann, Lisa E. Hensley, Thomas Geisbert

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). The main concern with all replication-competent vaccines, including the rVSV filovirus GP vectors, is their safety. To address this concern, we performed a neurovirulence study using 21 cynomolgus macaques where the vaccines were administered intrathalamically. Seven animals received a rVSV vector expressing the Zaire ebolavirus (ZEBOV) GP; seven animals received a rVSV vector expressing the Lake Victoria marburgvirus (MARV) GP; three animals received rVSV-wild type (wt) vector, and four animals received vehicle control. Two of three animals given rVSV-wt showed severe neurological symptoms whereas animals receiving vehicle control, rVSV-ZEBOV-GP, or rVSV-MARV-GP did not develop these symptoms. Histological analysis revealed major lesions in neural tissues of all three rVSV-wt animals; however, no significant lesions were observed in any animals from the filovirus vaccine or vehicle control groups. These data strongly suggest that rVSV filovirus GP vaccine vectors lack the neurovirulence properties associated with the rVSV-wt parent vector and support their further development as a vaccine platform for human use.

Original languageEnglish (US)
Article numbere1567
JournalPLoS Neglected Tropical Diseases
Volume6
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Vesicular Stomatitis
Primates
Glycoproteins
Vaccines
Viruses
Marburgvirus
Ebolavirus
Democratic Republic of the Congo
Synthetic Vaccines
Wild Animals
Macaca
Fever

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. / Mire, Chad; Miller, Andrew D.; Carville, Angela; Westmoreland, Susan V.; Geisbert, Joan B.; Mansfield, Keith G.; Feldmann, Heinz; Hensley, Lisa E.; Geisbert, Thomas.

In: PLoS Neglected Tropical Diseases, Vol. 6, No. 3, e1567, 03.2012.

Research output: Contribution to journalArticle

Mire, Chad ; Miller, Andrew D. ; Carville, Angela ; Westmoreland, Susan V. ; Geisbert, Joan B. ; Mansfield, Keith G. ; Feldmann, Heinz ; Hensley, Lisa E. ; Geisbert, Thomas. / Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. In: PLoS Neglected Tropical Diseases. 2012 ; Vol. 6, No. 3.
@article{a032ea83973f4346bd020031d8b6b38e,
title = "Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates",
abstract = "The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). The main concern with all replication-competent vaccines, including the rVSV filovirus GP vectors, is their safety. To address this concern, we performed a neurovirulence study using 21 cynomolgus macaques where the vaccines were administered intrathalamically. Seven animals received a rVSV vector expressing the Zaire ebolavirus (ZEBOV) GP; seven animals received a rVSV vector expressing the Lake Victoria marburgvirus (MARV) GP; three animals received rVSV-wild type (wt) vector, and four animals received vehicle control. Two of three animals given rVSV-wt showed severe neurological symptoms whereas animals receiving vehicle control, rVSV-ZEBOV-GP, or rVSV-MARV-GP did not develop these symptoms. Histological analysis revealed major lesions in neural tissues of all three rVSV-wt animals; however, no significant lesions were observed in any animals from the filovirus vaccine or vehicle control groups. These data strongly suggest that rVSV filovirus GP vaccine vectors lack the neurovirulence properties associated with the rVSV-wt parent vector and support their further development as a vaccine platform for human use.",
author = "Chad Mire and Miller, {Andrew D.} and Angela Carville and Westmoreland, {Susan V.} and Geisbert, {Joan B.} and Mansfield, {Keith G.} and Heinz Feldmann and Hensley, {Lisa E.} and Thomas Geisbert",
year = "2012",
month = "3",
doi = "10.1371/journal.pntd.0001567",
language = "English (US)",
volume = "6",
journal = "PLoS Neglected Tropical Diseases",
issn = "1935-2727",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates

AU - Mire, Chad

AU - Miller, Andrew D.

AU - Carville, Angela

AU - Westmoreland, Susan V.

AU - Geisbert, Joan B.

AU - Mansfield, Keith G.

AU - Feldmann, Heinz

AU - Hensley, Lisa E.

AU - Geisbert, Thomas

PY - 2012/3

Y1 - 2012/3

N2 - The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). The main concern with all replication-competent vaccines, including the rVSV filovirus GP vectors, is their safety. To address this concern, we performed a neurovirulence study using 21 cynomolgus macaques where the vaccines were administered intrathalamically. Seven animals received a rVSV vector expressing the Zaire ebolavirus (ZEBOV) GP; seven animals received a rVSV vector expressing the Lake Victoria marburgvirus (MARV) GP; three animals received rVSV-wild type (wt) vector, and four animals received vehicle control. Two of three animals given rVSV-wt showed severe neurological symptoms whereas animals receiving vehicle control, rVSV-ZEBOV-GP, or rVSV-MARV-GP did not develop these symptoms. Histological analysis revealed major lesions in neural tissues of all three rVSV-wt animals; however, no significant lesions were observed in any animals from the filovirus vaccine or vehicle control groups. These data strongly suggest that rVSV filovirus GP vaccine vectors lack the neurovirulence properties associated with the rVSV-wt parent vector and support their further development as a vaccine platform for human use.

AB - The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with high mortality in humans and nonhuman primates. Among the most promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses an individual filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). The main concern with all replication-competent vaccines, including the rVSV filovirus GP vectors, is their safety. To address this concern, we performed a neurovirulence study using 21 cynomolgus macaques where the vaccines were administered intrathalamically. Seven animals received a rVSV vector expressing the Zaire ebolavirus (ZEBOV) GP; seven animals received a rVSV vector expressing the Lake Victoria marburgvirus (MARV) GP; three animals received rVSV-wild type (wt) vector, and four animals received vehicle control. Two of three animals given rVSV-wt showed severe neurological symptoms whereas animals receiving vehicle control, rVSV-ZEBOV-GP, or rVSV-MARV-GP did not develop these symptoms. Histological analysis revealed major lesions in neural tissues of all three rVSV-wt animals; however, no significant lesions were observed in any animals from the filovirus vaccine or vehicle control groups. These data strongly suggest that rVSV filovirus GP vaccine vectors lack the neurovirulence properties associated with the rVSV-wt parent vector and support their further development as a vaccine platform for human use.

UR - http://www.scopus.com/inward/record.url?scp=84859181562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859181562&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0001567

DO - 10.1371/journal.pntd.0001567

M3 - Article

C2 - 22448291

AN - SCOPUS:84859181562

VL - 6

JO - PLoS Neglected Tropical Diseases

JF - PLoS Neglected Tropical Diseases

SN - 1935-2727

IS - 3

M1 - e1567

ER -